The emergence of Retatrutide ZPHC, at a concentration of 120mg, is generating considerable interest within the medical community. This innovative dual GIP and GLP-1 receptor medication appears to deliver impressive improvements in weight loss compared to previous therapies. Early research trials have demonstrated marked decreases in body fat percen